CHEK2 and breast carcinoma: Within Asia, a South Korean study of 235 patients at high-risk for hereditary breast cancer and were confirmed not to have a BRCA1/2 mutation were tested with massively parallel sequencing, and 3.6% were found to have pathogenic germline mutations in CHEK2, PALB2, MRE11 and RAD50 [13].